Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Merck KGaA Erbitux Trial Designed With FDA Feedback On ImClone U.S. Trials

Executive Summary

Merck KGaA's Erbitux Phase II trial in colorectal cancer will benefit from FDA feedback on ImClone's earlier U.S. trial designs, ImClone Chief Operating Officer Harlan Waksal said

You may also be interested in...

Bristol/ImClone Erbitux BLA Timeline Depends On Merck KGaA Phase II Study

ImClone's timeline for refiling its Erbitux BLA hinges on completion of Merck KGaA's Phase II study in colorectal cancer patients

ImClone Erbitux Options: Add EU Colorectal Data, Refile As Head & Neck BLA

ImClone may refile its Erbitux BLA in colorectal cancer using data from studies conducted by Merck KGaA, which holds the European rights to cetuximab

Bristol/ImClone Erbitux BLA Resubmission Expected During First Quarter

ImClone expects to resubmit the BLA for Erbitux (cetuximab) during the first quarter after addressing the issues raised in FDA's "refuse-to-file" letter for the colorectal cancer treatment




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts